Narrative review / 2011
Weight loss is the cornerstone treatment for NAFLD, while drug options targeting insulin resistance and other pathways continue to be investigated.
This review evaluates current and emerging therapeutic strategies for non-alcoholic fatty liver disease (NAFLD). Weight loss remains the cornerstone of treating hepatic steatosis, though it is difficult to achieve, and pragmatic approaches include general recommendations for weight loss and physical activity. Because insulin resistance is considered a pivotal factor in NAFLD and its progression, insulin sensitizers are viewed as a treatment of choice among pharmacotherapies.
- Study type
- Narrative review
- Who was studied
- Patients with non-alcoholic fatty liver disease (NAFLD)
- What was measured
- Treatment options for NAFLD, including weight loss, lifestyle, and emerging drugs
THE PAPER
Treatment of non-alcoholic fatty liver disease with focus on emerging drugs.
Marchesini G, Moscatiello S, Agostini F, Villanova N, Festi D. Expert Opin Emerg Drugs, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.